DK200400777A - Behandling og diagnosticering af insulin-resistente tilstande - Google Patents
Behandling og diagnosticering af insulin-resistente tilstande Download PDFInfo
- Publication number
- DK200400777A DK200400777A DK200400777A DKPA200400777A DK200400777A DK 200400777 A DK200400777 A DK 200400777A DK 200400777 A DK200400777 A DK 200400777A DK PA200400777 A DKPA200400777 A DK PA200400777A DK 200400777 A DK200400777 A DK 200400777A
- Authority
- DK
- Denmark
- Prior art keywords
- dkk
- seq
- residue
- insulin
- sequence
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Marine Sciences & Fisheries (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Obesity (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32994701P | 2001-10-15 | 2001-10-15 | |
PCT/US2002/032874 WO2003032810A2 (en) | 2001-10-15 | 2002-10-15 | Treatment and diagnosis of insulin resistant states |
Publications (1)
Publication Number | Publication Date |
---|---|
DK200400777A true DK200400777A (da) | 2004-05-14 |
Family
ID=23287695
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK200400777A DK200400777A (da) | 2001-10-15 | 2004-05-14 | Behandling og diagnosticering af insulin-resistente tilstande |
Country Status (17)
Country | Link |
---|---|
US (3) | US20030100504A1 (xx) |
JP (1) | JP2005506342A (xx) |
CN (1) | CN1571675A (xx) |
AT (1) | AT500646A1 (xx) |
CA (1) | CA2461818A1 (xx) |
CZ (1) | CZ2004564A3 (xx) |
DE (1) | DE10297331T5 (xx) |
DK (1) | DK200400777A (xx) |
ES (1) | ES2304072B1 (xx) |
FI (1) | FI20040531A (xx) |
GB (1) | GB2395903B (xx) |
HK (1) | HK1063280A1 (xx) |
IL (1) | IL161198A0 (xx) |
LU (1) | LU91070B1 (xx) |
MX (1) | MXPA04003536A (xx) |
SE (2) | SE528775C2 (xx) |
WO (1) | WO2003032810A2 (xx) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL1680112T3 (pl) * | 2003-10-29 | 2011-05-31 | Genzyme Corp | N-(5-adamantan-1-ylometoksypentylo)deoksynojirimycyna lub dopuszczalna farmaceutycznie sól stosowane w leczeniu oporności na insulinę |
WO2006010534A1 (en) * | 2004-07-28 | 2006-02-02 | F.Hoffmann-La Roche Ag | Dickkopf homolog 3 as target/marker of beta cell failure |
EP1827470A2 (en) * | 2004-12-09 | 2007-09-05 | Neuro Therapeutics AB | Materials and methods related to dickkopfs (dkk) and neurogenesis |
JPWO2006073195A1 (ja) * | 2005-01-07 | 2008-06-12 | 敏一 吉川 | 糖尿病の予知・診断方法および糖尿病予知・診断用キット |
CN1963511B (zh) * | 2005-11-11 | 2014-09-24 | 上海市肿瘤研究所 | Dkk-1蛋白在癌症诊断中的应用 |
MX2010012090A (es) | 2008-05-05 | 2011-04-11 | Novimmune Sa | Anticuerpos anti-il 17 a/il-17f de reactividad cruzada y metodos de uso de los mismos. |
BRPI1011535A2 (pt) * | 2009-04-01 | 2016-03-29 | Genentech Inc | tratamento de distúrbios resistentes à insulina. |
MA45536A (fr) * | 2016-06-30 | 2019-05-08 | Novo Nordisk As | Systèmes et procédés d'analyse de données d'adhérence au régime d'insuline |
CN115124424B (zh) * | 2022-06-01 | 2024-04-05 | 重庆市食品药品检验检测研究院 | 非诺贝特半抗原及其制备方法、非诺贝特抗原、抗体及其用途 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6187991B1 (en) * | 1995-05-23 | 2001-02-13 | Pfizer Inc | Transgenic animal models for type II diabetes mellitus |
-
2002
- 2002-10-15 US US10/271,628 patent/US20030100504A1/en not_active Abandoned
- 2002-10-15 MX MXPA04003536A patent/MXPA04003536A/es not_active Application Discontinuation
- 2002-10-15 CZ CZ2004564A patent/CZ2004564A3/cs unknown
- 2002-10-15 DE DE10297331T patent/DE10297331T5/de not_active Withdrawn
- 2002-10-15 CA CA002461818A patent/CA2461818A1/en not_active Abandoned
- 2002-10-15 ES ES200450027A patent/ES2304072B1/es not_active Withdrawn - After Issue
- 2002-10-15 GB GB0407486A patent/GB2395903B/en not_active Expired - Fee Related
- 2002-10-15 IL IL16119802A patent/IL161198A0/xx unknown
- 2002-10-15 WO PCT/US2002/032874 patent/WO2003032810A2/en not_active Application Discontinuation
- 2002-10-15 AT AT0924302A patent/AT500646A1/de not_active Application Discontinuation
- 2002-10-15 JP JP2003535620A patent/JP2005506342A/ja not_active Withdrawn
- 2002-10-15 CN CNA028204034A patent/CN1571675A/zh active Pending
- 2002-10-15 LU LU91070A patent/LU91070B1/en active
-
2004
- 2004-04-14 SE SE0400961A patent/SE528775C2/sv not_active IP Right Cessation
- 2004-04-14 FI FI20040531A patent/FI20040531A/fi not_active IP Right Cessation
- 2004-05-14 DK DK200400777A patent/DK200400777A/da not_active Application Discontinuation
- 2004-08-12 HK HK04106068A patent/HK1063280A1/xx not_active IP Right Cessation
-
2005
- 2005-02-11 US US11/056,562 patent/US20050170440A1/en not_active Abandoned
-
2006
- 2006-08-21 US US11/465,956 patent/US20060293239A1/en not_active Abandoned
- 2006-11-27 SE SE0602516A patent/SE0602516L/sv not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
US20060293239A1 (en) | 2006-12-28 |
WO2003032810A2 (en) | 2003-04-24 |
ES2304072B1 (es) | 2009-07-07 |
FI20040531A (fi) | 2004-04-14 |
DE10297331T5 (de) | 2004-11-18 |
SE0400961L (sv) | 2004-04-14 |
CZ2004564A3 (cs) | 2005-03-16 |
IL161198A0 (en) | 2004-08-31 |
US20030100504A1 (en) | 2003-05-29 |
GB2395903A (en) | 2004-06-09 |
CN1571675A (zh) | 2005-01-26 |
SE0602516L (sv) | 2006-11-27 |
LU91070B1 (en) | 2004-04-15 |
ES2304072A1 (es) | 2008-09-01 |
WO2003032810A3 (en) | 2004-06-17 |
SE0400961D0 (sv) | 2004-04-14 |
HK1063280A1 (en) | 2004-12-24 |
JP2005506342A (ja) | 2005-03-03 |
GB2395903B (en) | 2005-08-31 |
AT500646A1 (de) | 2006-02-15 |
US20050170440A1 (en) | 2005-08-04 |
CA2461818A1 (en) | 2003-04-24 |
GB0407486D0 (en) | 2004-05-05 |
SE528775C2 (sv) | 2007-02-13 |
MXPA04003536A (es) | 2004-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Imanaka‐Yoshida et al. | Tenascin‐C is a useful marker for disease activity in myocarditis | |
EP2109624B1 (en) | Diagnostic methods for diseases by screening for hepcidin in human or animal tissues, blood or body fluids, monoclonal antibodies specific to human hepcidin and associated uses therefor | |
DE202021100842U1 (de) | Methoden und Reagenzien zur Diagnose einer SARS-CoV-2-Infektion | |
US8026345B2 (en) | Characterization and identification of unique human adiponectin isoforms and antibodies | |
EP2336161B1 (de) | Amyloid-beta(1-42)-Oligomere, Derivate davon und Antikörper dafür, Verfahren zu deren Herstellung und deren Verwendung | |
CN1910456B (zh) | 视神经脊髓炎的标记 | |
AU2009224114B2 (en) | Biomarkers | |
Burke et al. | Neuron‐specific expression of a synaptotagmin gene in the sea urchin Strongylocentrotus purpuratus | |
KR101316990B1 (ko) | 항-α9 인테그린 항체와 그 용도 | |
DK200400777A (da) | Behandling og diagnosticering af insulin-resistente tilstande | |
WO1998015179A1 (en) | Therapeutic and diagnostic applications of laminin and laminin-derived protein fragments | |
Inagaki et al. | IgG anti‐laminin‐1 autoantibody and recurrent miscarriages | |
JP2005527235A (ja) | デフェンシン:抗ウイルス剤の使用 | |
CN103140498B (zh) | 信号生物标志物 | |
Menge et al. | Relevant antibody subsets against MOG recognize conformational epitopes exclusively exposed in solid‐phase ELISA | |
US20090047686A1 (en) | Methods for identifying and producing specific amino acid dependent antibodies and uses thereof | |
EP0514481B1 (en) | Merosin, nucleic acids encoding, fragments and uses thereof | |
US20110189201A1 (en) | Modulation of bone development | |
CA2715914C (en) | Insulin signal peptide fragment biomarkers | |
Chronopoulos et al. | Ubiquitin: its potential significance in murine AA amyloidogenesis | |
CA2612303A1 (en) | Anti-glycated cd59 antibodies and uses thereof | |
CN114702577B (zh) | 一种广谱识别西尼罗病毒以及寨卡病毒e蛋白diii的抗体 | |
Traish et al. | Identification of structurally altered estrogen receptors in human breast cancer by site-directed monoclonal antibodies | |
WO2021138273A2 (en) | Autoantibodies as biomarkers for autoimmune polyglandular syndrome type 1 | |
US5624905A (en) | Merosin fragments and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AHS | Application shelved for other reasons than non-payment |